Scandinavian ChemoTech publishes clinical strategy update from Medical Director Dr. Suhail Mufti

Scandinavian ChemoTech has published an updated clinical strategy from the company´s Medical Director Dr. Suhail Mufti.

The presentation can be accessed through ChemoTech's YouTube channel:

https://www.youtube.com/@scandinavianchemotechabpub4074

It has also been uploaded to ChemoTech´s website:

https://www.chemotech.se/investor-relations/presentations/

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.